AMGN
EquityAmgen Inc.
Health Care · Drug Manufacturers - General
$388.16
+388.16 (+0.00%)
Open
N/A
Day Range
$378.75 - $390.10
52W Range
$261.43 - $390.10
Volume
3M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Generate caps a strong month for biotech IPOs with $400M offering
Physician-Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
Is Amgen Stock Outperforming the Dow?
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| 001540.KQ | AHN-GOOK PHA | $8,070.00 | N/A | 5.45% | +0.00% |
| ABBV | AbbVie Inc. | $232.06 | N/A | 2.87% | +0.00% |
| LLY | Eli Lilly and Company | $1,052.20 | N/A | 0.59% | +0.00% |
| NVO | Novo Nordisk A/S | $37.46 | N/A | 4.49% | +0.00% |
| EJG.F | EBOS Group Ltd. R | $11.70 | N/A | 5.14% | +0.00% |
| 5889.T | JAPAN EYEWEAR HOLDINGS CO LTD | $1,998.00 | N/A | 4.20% | +0.00% |
| 0332.KL | TOPVISN | $0.17 | N/A | 11.76% | +0.00% |
| ABT | Abbott Laboratories | $116.32 | N/A | 2.06% | +0.00% |
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
www.amgen.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+5.8%
3Y CAGR
+7.1%
5Y CAGR
N/A
10Y CAGR
N/A
Loading financial data...
Revenue & Earnings
No financial statement data available for AMGN.